SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing intense momentum fueled by a fresh defense contract and broader investor interest in memory hardware for AI and data centers. The community is actively debating the potential for a short squeeze, balancing excitement over the company's patented technology and military-grade applications against concerns regarding high valuations and pending legal issues.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as investors rotate back into Japanese blockchain projects and IoT-focused assets. While community sentiment remains polarized between long-term holders citing ecosystem expansion and skeptics highlighting a lack of official partnership news, traders are closely monitoring technical breakouts and exchange accumulation trends.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as the community closely monitors the potential Senate markup of the Clarity Act, which many believe could provide the regulatory framework necessary to unlock institutional capital. While some investors remain frustrated by recent price consolidation, others are actively tracking increased ETF inflows and new integration partnerships as signals that structural adoption is building for the long term.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the FDA moves to block compounded versions of popular GLP-1 weight-loss drugs, a significant catalyst that strengthens the brand dominance of official products like Wegovy and Ozempic. The community is actively discussing this regulatory shift, with many investors anticipating that the reduced competition will accelerate adoption, boost market share, and act as a tailwind heading into the upcoming earnings report.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Investors are actively debating the future of CRO, with community sentiment split between frustration over persistent token dilution and optimism regarding potential ETF filings and mobile app developments. While some participants are aggressively accumulating, others remain wary, highlighting concerns over management transparency and historical underperformance relative to broader market gains.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention as it transitions toward a sovereign cloud infrastructure model, with active discussions focusing on its potential to offer an alternative to centralized Big Tech providers like AWS. While investors are debating the long-term impact of deflationary tokenomics and network activity, the community is closely monitoring institutional interest and technical development milestones as catalysts for potential momentum.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following a corporate update regarding financial results and the company's progress toward a pivotal Phase 3 clinical trial for its lead candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some community members are optimistic about the upcoming trial registration path and orphan drug designations, others are expressing skepticism, focusing on potential share dilution and concerns over aggressive social media promotion.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as community members aggressively debate its long-term potential as a high-speed institutional settlement layer, often citing its reported partnership history and infrastructure capabilities. The discussion is heavily polarized between bullish investors highlighting its 11M TPS architecture and potential fintech use cases versus skeptics who dismiss the activity as repetitive spam or an unproven pump-and-dump scheme.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera (HBAR) is seeing active community discussion as investors debate its long-term enterprise utility versus ongoing concerns regarding token dilution and price performance. While some participants are accumulating positions in anticipation of future institutional adoption and network upgrades, others are skeptical, focusing on the heavy token supply and historical price volatility.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate the impact of the newly launched spot ETF against a backdrop of broader market volatility and institutional interest in RWA tokenization. Community sentiment is deeply polarized, with many users expressing frustration over recent price declines while long-term holders actively accumulate positions in anticipation of a potential bull cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,132,986...

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire SAN FRANCISCO, April 10, 2026 SAN...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are currently covering the stock...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD)

BTIG Research reaffirmed a "buy" rating and set a $9.00 target price on shares of Aardvark Therapeutics in a research note on Tuesday...

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

AARD
Aardvark Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AARD News

AARDAardvark Therapeutics Inc